;PMID: 3919053
;source_file_964.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..47] = [t:0..47]
;1)sentence:[e:53..191] = [t:53..191]
;2)section:[e:195..251] = [t:195..251]
;3)sentence:[e:255..549] = [t:255..549]
;4)sentence:[e:550..705] = [t:550..705]
;5)sentence:[e:706..906] = [t:706..906]
;6)sentence:[e:907..1098] = [t:907..1098]
;7)sentence:[e:1099..1286] = [t:1099..1286]
;8)sentence:[e:1287..1572] = [t:1287..1572]
;9)sentence:[e:1573..1665] = [t:1573..1665]
;10)sentence:[e:1666..1833] = [t:1666..1833]
;11)sentence:[e:1834..2309] = [t:1834..2309]
;12)section:[e:2313..2357] = [t:2313..2357]

;section 0 Span:0..47
;J Clin Endocrinol Metab. 1985 Apr;60(4):773-80.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Clin) (NNP:[7..17] Endocrinol)
        (NNP:[18..23] Metab) (.:[23..24] .) (CD:[25..29] 1985)
        (.:[30..37] Apr;60-LRB-) (CD:[37..39] 4-RRB-) (CD:[39..43] :773)
        (HYPH:[43..44] -) (CD:[44..46] 80) (.:[46..47] .)))

;sentence 1 Span:53..191
;The effects of the aromatase inhibitor delta 1-testolactone on gonadotropin 
;release and steroid metabolism in polycystic ovarian disease.
;[72..81]:substance:"aromatase"
;[82..91]:substance:"inhibitor"
;[92..112]:substance:"delta 1-testolactone"
;[116..128]:substance:"gonadotropin"
;[142..149]:substance:"steroid"
(SENT
  (NP-HLN
    (NP (DT:[53..56] The) (NNS:[57..64] effects))
    (PP (IN:[65..67] of)
      (NP
        (NP (DT:[68..71] the) (NN:[72..81] aromatase) (NN:[82..91] inhibitor))
        (NP (SYM:[92..97] delta) (NN:[98..112] 1-testolactone))))
    (PP (IN:[113..115] on)
      (NP
        (NP (NN:[116..128] gonadotropin) (NN:[130..137] release))
        (CC:[138..141] and)
        (NP (JJ:[142..149] steroid) (NN:[150..160] metabolism))))
    (PP (IN:[161..163] in)
      (NP (JJ:[164..174] polycystic) (JJ:[175..182] ovarian)
          (NN:[183..190] disease)))
    (.:[190..191] .)))

;section 2 Span:195..251
;Dunaif A, Longcope C, Canick J, Badger T, Crowley WF Jr.
(SEC
  (FRAG (NNP:[195..201] Dunaif) (NNP:[202..203] A) (,:[203..204] ,)
        (NNP:[205..213] Longcope) (NNP:[214..215] C) (,:[215..216] ,)
        (NNP:[217..223] Canick) (NNP:[224..226] J,) (NNP:[227..233] Badger)
        (NNP:[234..235] T) (,:[235..236] ,) (NNP:[237..244] Crowley)
        (NNP:[245..247] WF) (NNP:[248..251] Jr.)))

;sentence 3 Span:255..549
;This study was designed to examine the importance of aromatization in the 
;gonadotropin secretory dynamics of polycystic ovarian disease (PCOD) by using
; the aromatase inhibitor delta 1 testolactone (TL) as a probe and to
;determine  the effects of TL on steroid metabolism in vivo and in vitro.
;[330..342]:substance:"gonadotropin"
;[413..422]:substance:"aromatase"
;[423..432]:substance:"inhibitor"
;[433..453]:substance:"delta 1 testolactone"
;[455..457]:substance:"TL"
;[464..469]:substance:"probe"
;[503..505]:substance:"TL"
;[509..516]:substance:"steroid"
(SENT
  (S
    (NP-SBJ-1 (DT:[255..259] This) (NN:[260..265] study))
    (VP (VBD:[266..269] was)
      (VP (VBN:[270..278] designed)
        (NP-1 (-NONE-:[278..278] *))
        (S-PRP
          (NP-SBJ (-NONE-:[278..278] *))
          (VP
            (VP (TO:[279..281] to)
              (VP (VB:[282..289] examine)
                (NP
                  (NP (DT:[290..293] the) (NN:[294..304] importance))
                  (PP (IN:[305..307] of)
                    (NP (NN:[308..321] aromatization))))
                (PP (IN:[322..324] in)
                  (NP
                    (NP (DT:[325..328] the) (NN:[330..342] gonadotropin)
                        (JJ:[343..352] secretory) (NNS:[353..361] dynamics))
                    (PP (IN:[362..364] of)
                      (NP
                        (NP (JJ:[365..375] polycystic) (JJ:[376..383] ovarian)
                            (NN:[384..391] disease))
                        (NP (-LRB-:[392..393] -LRB-) (NN:[393..397] PCOD)
                            (-RRB-:[397..398] -RRB-))))))
                (PP-MNR (IN:[399..401] by)
                  (S-NOM
                    (NP-SBJ (-NONE-:[401..401] *))
                    (VP (VBG:[402..407] using)
                      (NP
                        (NP (DT:[409..412] the) (NN:[413..422] aromatase)
                            (NN:[423..432] inhibitor))
                        (NP
                          (NP (SYM:[433..438] delta) (CD:[439..440] 1)
                              (NN:[441..453] testolactone))
                          (NP (-LRB-:[454..455] -LRB-) (NN:[455..457] TL)
                              (-RRB-:[457..458] -RRB-))))
                      (PP (IN:[459..461] as)
                        (NP (DT:[462..463] a) (NN:[464..469] probe))))))))
            (CC:[470..473] and)
            (VP (TO:[474..476] to)
              (VP (VB:[477..486] determine)
                (NP
                  (NP (DT:[488..491] the) (NNS:[492..499] effects))
                  (PP (IN:[500..502] of)
                    (NP (NN:[503..505] TL)))
                  (PP (IN:[506..508] on)
                    (NP (JJ:[509..516] steroid) (NN:[517..527] metabolism))))
                (ADVP
                  (ADVP (FW:[528..530] in) (FW:[531..535] vivo))
                  (CC:[536..539] and)
                  (ADVP (FW:[540..542] in) (FW:[543..548] vitro)))))))))
    (.:[548..549] .)))

;sentence 4 Span:550..705
;The pulsatile  patterns of gonadotropin secretion and peripheral steroid
;levels were studied in  eight women with PCOD before and during TL
;administration.
;[577..589]:substance:"gonadotropin"
;[615..622]:substance:"steroid"
;[687..689]:substance:"TL"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[550..553] The) (JJ:[554..563] pulsatile)
          (NNS:[565..573] patterns))
      (PP (IN:[574..576] of)
        (NP
          (NP (NN:[577..589] gonadotropin) (NN:[590..599] secretion))
          (CC:[600..603] and)
          (NP (JJ:[604..614] peripheral) (JJ:[615..622] steroid)
              (NNS:[623..629] levels)))))
    (VP (VBD:[630..634] were)
      (VP (VBN:[635..642] studied)
        (NP-1 (-NONE-:[642..642] *))
        (PP-LOC (IN:[643..645] in)
          (NP
            (NP (CD:[647..652] eight) (NNS:[653..658] women))
            (PP (IN:[659..663] with)
              (NP (NN:[664..668] PCOD)))))
        (PP-TMP (IN:[669..675] before) (CC:[676..679] and)
                (IN:[680..686] during)
          (NP (NN:[687..689] TL) (NN:[690..704] administration)))))
    (.:[704..705] .)))

;sentence 5 Span:706..906
;There was a  significant fall in peripheral estrone (E1) levels, a rise in
;peripheral  androstenedione levels, and an increase in the androstenedione/E1
;ratio during  TL administration in these women.
;[750..757]:substance:"estrone"
;[759..761]:substance:"E1"
;[793..808]:substance:"androstenedione"
;[840..855]:substance:"androstenedione"
;[856..858]:substance:"E1"
;[873..875]:substance:"TL"
(SENT
  (S
    (NP-SBJ (EX:[706..711] There))
    (VP (VBD:[712..715] was)
      (NP-PRD
        (NP
          (NP (DT:[716..717] a) (JJ:[719..730] significant) (NN:[731..735] fall))
          (PP (IN:[736..738] in)
            (NP
              (NML
                (NML (JJ:[739..749] peripheral) (NN:[750..757] estrone))
                (NML (-LRB-:[758..759] -LRB-) (NN:[759..761] E1)
                     (-RRB-:[761..762] -RRB-)))
              (NNS:[763..769] levels))))
        (,:[769..770] ,)
        (NP
          (NP (DT:[771..772] a) (NN:[773..777] rise))
          (PP (IN:[778..780] in)
            (NP (JJ:[781..791] peripheral) (NN:[793..808] androstenedione)
                (NNS:[809..815] levels))))
        (,:[815..816] ,) (CC:[817..820] and)
        (NP
          (NP (DT:[821..823] an) (NN:[824..832] increase))
          (PP (IN:[833..835] in)
            (NP (DT:[836..839] the)
              (NML
                (NML (NN:[840..855] androstenedione))
                (PP (SYM:[855..856] /)
                  (NP (NN:[856..858] E1))))
              (NN:[859..864] ratio)))))
      (PP-TMP (IN:[865..871] during)
        (NP (NN:[873..875] TL) (NN:[876..890] administration)))
      (PP-LOC (IN:[891..893] in)
        (NP (DT:[894..899] these) (NNS:[900..905] women))))
    (.:[905..906] .)))

;sentence 6 Span:907..1098
;Isotopic determinations of androgen and  estrogen production and metabolism
;before and during TL administration in two  women confirmed a 90-95% decrease
;in the overall rate of aromatization.
;[934..942]:substance:"androgen"
;[948..956]:substance:"estrogen"
;[1001..1003]:substance:"TL"
;[1045..1051]:quantitative-value:"90-95%"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[907..915] Isotopic) (NNS:[916..930] determinations))
      (PP (IN:[931..933] of)
        (NP
          (NP
            (NML-1 (NN:[934..942] androgen) (CC:[943..946] and)
                   (NN:[948..956] estrogen))
            (NN:[957..967] production))
          (CC:[968..971] and)
          (NP
            (NML-1 (-NONE-:[971..971] *P*))
            (NN:[972..982] metabolism))))
      (PP-TMP (IN:[983..989] before) (CC:[990..993] and) (IN:[994..1000] during)
        (NP (NN:[1001..1003] TL) (NN:[1004..1018] administration)))
      (PP-LOC (IN:[1019..1021] in)
        (NP (CD:[1022..1025] two) (NNS:[1027..1032] women))))
    (VP (VBD:[1033..1042] confirmed)
      (NP
        (NP (DT:[1043..1044] a)
          (NML
            (QP (CD:[1045..1047] 90) (HYPH:[1047..1048] -) (CD:[1048..1050] 95))
            (NN:[1050..1051] %))
          (NN:[1052..1060] decrease))
        (PP (IN:[1061..1063] in)
          (NP
            (NP (DT:[1064..1067] the) (JJ:[1068..1075] overall)
                (NN:[1076..1080] rate))
            (PP (IN:[1081..1083] of)
              (NP (NN:[1084..1097] aromatization)))))))
    (.:[1097..1098] .)))

;sentence 7 Span:1099..1286
;One  patient also had an increase in the production and clearance rates of
;estradiol  and E1 during TL administration, suggesting resistance to TL of
;the ovarian  aromatase enzyme system.
;[1174..1183]:substance:"estradiol"
;[1189..1191]:substance:"E1"
;[1199..1201]:substance:"TL"
;[1243..1245]:substance:"TL"
;[1262..1278]:substance:"aromatase enzyme"
(SENT
  (S
    (NP-SBJ (CD:[1099..1102] One) (NN:[1104..1111] patient))
    (ADVP (RB:[1112..1116] also))
    (VP (VBD:[1117..1120] had)
      (NP
        (NP (DT:[1121..1123] an) (NN:[1124..1132] increase))
        (PP (IN:[1133..1135] in)
          (NP
            (PP (DT:[1136..1139] the)
              (NML
                (NML (NN:[1140..1150] production)
                  (NML-1 (-NONE-:[1150..1150] *P*)))
                (CC:[1151..1154] and)
                (NML (NN:[1155..1164] clearance)
                  (NML-1 (NNS:[1165..1170] rates)))))
            (PP (IN:[1171..1173] of)
              (NP (NN:[1174..1183] estradiol) (CC:[1185..1188] and)
                  (NN:[1189..1191] E1))))))
      (PP-TMP (IN:[1192..1198] during)
        (NP (NN:[1199..1201] TL) (NN:[1202..1216] administration)))
      (,:[1216..1217] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1217..1217] *))
        (VP (VBG:[1218..1228] suggesting)
          (NP
            (NP (NN:[1229..1239] resistance))
            (PP (TO:[1240..1242] to)
              (NP (NN:[1243..1245] TL)))
            (PP (IN:[1246..1248] of)
              (NP (DT:[1249..1252] the) (JJ:[1253..1260] ovarian)
                 (NN:[1262..1271] aromatase) (NN:[1272..1278] enzyme)
                (NN:[1279..1285] system)))))))
    (.:[1285..1286] .)))

;sentence 8 Span:1287..1572
;There were significant increases in both mean LH pulse  amplitude [1.2 +/-
;0.3 (SE) mIU/ml LER-907 before vs. 1.7 +/- 0.3 mIU/ml LER-907  during TL, P
;less than 0.05, paired t test] and frequency per 6 h (median: 3  before vs. 4
;during TL, P less than 0.05, Wilcoxon signed rank test).
;[1333..1335]:substance:"LH"
;[1354..1365]:quantitative-value:"1.2 +/- 0.3"
;[1371..1385]:quantitative-units:"mIU/ml LER-907"
;[1397..1408]:quantitative-value:"1.7 +/- 0.3"
;[1409..1423]:quantitative-units:"mIU/ml LER-907"
;[1432..1434]:substance:"TL"
;[1487..1488]:quantitative-value:"6"
;[1489..1490]:quantitative-units:"h"
;[1500..1501]:quantitative-value:"3"
;[1514..1515]:quantitative-value:"4"
;[1523..1525]:substance:"TL"
(SENT
  (S
    (NP-SBJ (EX:[1287..1292] There))
    (VP (VBD:[1293..1297] were)
      (NP-PRD
        (NP (JJ:[1298..1309] significant) (NNS:[1310..1319] increases))
        (PP (IN:[1320..1322] in)
          (NP (CC:[1323..1327] both)
            (NP (JJ:[1328..1332] mean) (NN:[1333..1335] LH)
                (NN:[1336..1341] pulse) (NN:[1343..1352] amplitude)
              (PRN (-LRB-:[1353..1354] -LSB-)
                (FRAG
                  (NP
                    (NP
                      (NP
                        (NML
                          (NML
                            (QP (CD:[1354..1357] 1.2) (SYM:[1358..1361] +/-)
                                (CD:[1362..1365] 0.3))
                            (PRN (-LRB-:[1366..1367] -LRB-)
                              (NP (NN:[1367..1369] SE))
                              (-RRB-:[1369..1370] -RRB-))
                            (NN:[1371..1374] mIU))
                          (PP (SYM:[1374..1375] /)
                            (NP (NN:[1375..1377] ml))))
                        (NN:[1378..1385] LER-907))
                      (PP-TMP (IN:[1386..1392] before)
                        (NP-1 (-NONE-:[1392..1392] *RNR*))))
                    (IN:[1393..1396] vs.)
                    (NP
                      (NP
                        (NML
                          (NML
                            (QP (CD:[1397..1400] 1.7) (SYM:[1401..1404] +/-)
                                (CD:[1405..1408] 0.3))
                            (NN:[1409..1412] mIU))
                          (PP (SYM:[1412..1413] /)
                            (NP (NN:[1413..1415] ml))))
                        (NN:[1416..1423] LER-907))
                      (PP-TMP (IN:[1425..1431] during)
                        (NP-1 (-NONE-:[1431..1431] *RNR*))))
                    (NP-1 (NN:[1432..1434] TL)))
                  (,:[1434..1435] ,)
                  (FRAG
                    (S
                      (NP-SBJ (NN:[1436..1437] P))
                      (NP-PRD
                        (QP (JJR:[1438..1442] less) (IN:[1443..1447] than)
                            (CD:[1448..1452] 0.05))))
                    (,:[1452..1453] ,)
                    (NP (VBN:[1454..1460] paired) (NN:[1461..1462] t)
                        (NN:[1463..1467] test))))
                (-RRB-:[1467..1468] -RSB-)))
            (CC:[1469..1472] and)
            (NP
              (NP (NN:[1473..1482] frequency))
              (PP (IN:[1483..1486] per)
                (NP (CD:[1487..1488] 6) (NN:[1489..1490] h)))
              (PRN (-LRB-:[1491..1492] -LRB-)
                (FRAG
                  (S
                    (NP-SBJ (NN:[1492..1498] median))
                    (::[1498..1499] :)
                    (NP-PRD
                      (NP
                        (NP (CD:[1500..1501] 3))
                        (PP (IN:[1503..1509] before)
                          (NP-2 (-NONE-:[1509..1509] *RNR*))))
                      (IN:[1510..1513] vs.)
                      (NP
                        (NP (CD:[1514..1515] 4))
                        (PP (IN:[1516..1522] during)
                          (NP-2 (-NONE-:[1522..1522] *RNR*))))
                      (NP-2 (NN:[1523..1525] TL))))
                  (,:[1525..1526] ,)
                  (FRAG
                    (S
                      (NP-SBJ (NN:[1527..1528] P))
                      (NP-PRD
                        (QP (JJR:[1529..1533] less) (IN:[1534..1538] than)
                            (CD:[1539..1543] 0.05))))
                    (,:[1543..1544] ,)
                    (NP (NNP:[1545..1553] Wilcoxon) (VBN:[1554..1560] signed)
                        (NN:[1561..1565] rank) (NN:[1566..1570] test))))
                (-RRB-:[1570..1571] -RRB-)))))))
    (.:[1571..1572] .)))

;sentence 9 Span:1573..1665
;Mean  levels of LH and FSH did not, however, change significantly during TL 
;administration.
;[1589..1591]:substance:"LH"
;[1596..1599]:substance:"FSH"
;[1646..1648]:substance:"TL"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1573..1577] Mean) (NNS:[1579..1585] levels))
      (PP (IN:[1586..1588] of)
        (NP (NN:[1589..1591] LH) (CC:[1592..1595] and) (NN:[1596..1599] FSH))))
    (VP (VBD:[1600..1603] did) (RB:[1604..1607] not) (,:[1607..1608] ,)
      (ADVP (RB:[1609..1616] however))
      (,:[1616..1617] ,)
      (VP (VB:[1618..1624] change)
        (ADVP (RB:[1625..1638] significantly))
        (PP-TMP (IN:[1639..1645] during)
          (NP (NN:[1646..1648] TL) (NN:[1650..1664] administration)))))
    (.:[1664..1665] .)))

;sentence 10 Span:1666..1833
;TL maximally inhibited neonatal rat hypothalamic aromatase in  vitro at
;concentrations of 200 microM, a level theoretically obtainable during 
;pharmacological therapy.
;[1666..1668]:substance:"TL"
;[1715..1724]:substance:"aromatase"
;[1756..1759]:quantitative-value:"200"
;[1760..1766]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (NN:[1666..1668] TL))
    (ADVP (RB:[1669..1678] maximally))
    (VP (VBD:[1679..1688] inhibited)
      (NP (JJ:[1689..1697] neonatal) (NN:[1698..1701] rat)
          (JJ:[1702..1714] hypothalamic) (NN:[1715..1724] aromatase))
      (ADVP (FW:[1725..1727] in) (FW:[1729..1734] vitro))
      (PP (IN:[1735..1737] at)
        (NP
          (NP
            (NP (NNS:[1738..1752] concentrations))
            (PP (IN:[1753..1755] of)
              (NP (CD:[1756..1759] 200) (NN:[1760..1766] microM))))
          (,:[1766..1767] ,)
          (NP
            (NP (DT:[1768..1769] a) (NN:[1770..1775] level))
            (RRC
              (ADJP (RB:[1776..1789] theoretically) (JJ:[1790..1800] obtainable))
              (PP-TMP (IN:[1801..1807] during)
                (NP (JJ:[1809..1824] pharmacological) (NN:[1825..1832] therapy))))))))
    (.:[1832..1833] .)))

;sentence 11 Span:1834..2309
;These data suggest that: 1) in humans TL is a potent  inhibitor of peripheral
;but not ovarian aromatase, and of hypothalamic aromatase  in rats; 2) TL
;administration increases LH pulse amplitude and frequency in  PCOD, either
;directly via hypothalamic aromatase inhibition, or indirectly by  alterations
;in gonadal steroid metabolism; and 3) because of the multiple  potential
;actions of TL, its usefulness as a probe in studies of gonadotropin 
;secretion in PCOD is limited.
;[1872..1874]:substance:"TL"
;[1888..1897]:substance:"inhibitor"
;[1928..1937]:substance:"aromatase"
;[1959..1968]:substance:"aromatase"
;[1982..1984]:substance:"TL"
;[2010..2012]:substance:"LH"
;[2086..2095]:substance:"aromatase"
;[2149..2156]:substance:"steroid"
;[2222..2224]:substance:"TL"
;[2246..2251]:substance:"probe"
;[2266..2278]:substance:"gonadotropin"
(SENT
  (S
    (NP-SBJ (DT:[1834..1839] These) (NNS:[1840..1844] data))
    (VP (VBP:[1845..1852] suggest)
      (SBAR (IN:[1853..1857] that) (::[1857..1858] :)
        (S
          (S
            (LST (LS:[1859..1861] 1-RRB-))
            (PP-LOC (IN:[1862..1864] in)
              (NP (NNS:[1865..1871] humans)))
            (NP-SBJ (NN:[1872..1874] TL))
            (VP (VBZ:[1875..1877] is)
              (NP-PRD
                (NP (DT:[1878..1879] a) (JJ:[1880..1886] potent)
                    (NN:[1888..1897] inhibitor))
                (PP
                  (PP (IN:[1898..1900] of)
                    (NP
                      (NP (JJ:[1901..1911] peripheral)
                        (NML-4 (-NONE-:[1911..1911] *P*)))
                      (CONJP (CC:[1912..1915] but) (RB:[1916..1919] not))
                      (NP (JJ:[1920..1927] ovarian)
                        (NML-4 (NN:[1928..1937] aromatase)))))
                  (,:[1937..1938] ,) (CC:[1939..1942] and)
                  (PP (IN:[1943..1945] of)
                    (NP
                      (NP (JJ:[1946..1958] hypothalamic)
                          (NN:[1959..1968] aromatase))
                      (PP-LOC (IN:[1970..1972] in)
                        (NP (NNS:[1973..1977] rats)))))))))
          (::[1977..1978] ;)
          (S
            (LST (LS:[1979..1981] 2-RRB-))
            (NP-SBJ (NN:[1982..1984] TL) (NN:[1985..1999] administration))
            (VP (VBZ:[2000..2009] increases)
              (NP
                (NP
                  (NML-3 (NN:[2010..2012] LH))
                  (NML-2 (NN:[2013..2018] pulse))
                  (NN:[2019..2028] amplitude))
                (CC:[2029..2032] and)
                (NP
                  (NML-3 (-NONE-:[2032..2032] *P*))
                  (NML-2 (-NONE-:[2032..2032] *P*))
                  (NN:[2033..2042] frequency)))
              (PP (IN:[2043..2045] in)
                (NP (NN:[2047..2051] PCOD)))
              (,:[2051..2052] ,)
              (FRAG-MNR (CC:[2053..2059] either)
                (FRAG
                  (ADVP (RB:[2060..2068] directly))
                  (PP (IN:[2069..2072] via)
                    (NP (JJ:[2073..2085] hypothalamic)
                        (NN:[2086..2095] aromatase) (NN:[2096..2106] inhibition))))
                (,:[2106..2107] ,) (CC:[2108..2110] or)
                (FRAG
                  (ADVP (RB:[2111..2121] indirectly))
                  (PP (IN:[2122..2124] by)
                    (NP
                      (NP (NNS:[2126..2137] alterations))
                      (PP (IN:[2138..2140] in)
                        (NP (JJ:[2141..2148] gonadal) (JJ:[2149..2156] steroid)
                            (NN:[2157..2167] metabolism)))))))))
          (::[2167..2168] ;) (CC:[2169..2172] and)
          (S
            (LST (LS:[2173..2175] 3-RRB-))
            (PP (IN:[2176..2183] because)
              (PP (IN:[2184..2186] of)
                (NP
                  (NP (DT:[2187..2190] the) (JJ:[2191..2199] multiple)
                      (JJ:[2201..2210] potential) (NNS:[2211..2218] actions))
                  (PP (IN:[2219..2221] of)
                    (NP (NN:[2222..2224] TL))))))
            (,:[2224..2225] ,)
            (NP-SBJ-1
              (NP (PRP$:[2226..2229] its) (NN:[2230..2240] usefulness))
              (PP (IN:[2241..2243] as)
                (NP (DT:[2244..2245] a) (NN:[2246..2251] probe)))
              (PP (IN:[2252..2254] in)
                (NP
                  (NP (NNS:[2255..2262] studies))
                  (PP (IN:[2263..2265] of)
                    (NP
                      (NP (NN:[2266..2278] gonadotropin)
                          (NN:[2280..2289] secretion))
                      (PP (IN:[2290..2292] in)
                        (NP (NN:[2293..2297] PCOD))))))))
            (VP (VBZ:[2298..2300] is)
              (VP (VBN:[2301..2308] limited)
                (NP-1 (-NONE-:[2308..2308] *))))))))
    (.:[2308..2309] .)))

;section 12 Span:2313..2357
;PMID: 3919053 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2313..2317] PMID) (::[2317..2318] :) (CD:[2319..2326] 3919053)
        (NN:[2327..2328] -LSB-) (NNP:[2328..2334] PubMed) (::[2335..2336] -)
        (NN:[2337..2344] indexed) (IN:[2345..2348] for)
        (NNP:[2349..2357] MEDLINE-RSB-)))
